Jakub Fichna

Structure-activity relationship, conformation and pharmacology studies of morphiceptin analogues--selective mu-opioid receptor ligands.

Synthesis of target-specific radiolabeled peptides for diagnostic imaging.

Opioid receptors and their ligands.

Opioid peptides in cancer.

Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position.

Characterization of the [125I]endomorphin-2 binding sites in the MCF7 breast cancer cell line.

Inhibition of trigemino-hypoglossal reflex in rats by oxytocin is mediated by mu and kappa opioid receptors.

Comparison of antagonist activity of spantide family at human neurokinin receptors measured by aequorin luminescence-based functional calcium assay.

Enzymatic degradation studies of endomorphin-2 and its analogs containing N-methylated amino acids.

Synthesis and antinociceptive activity of cyclic endomorphin-2 and morphiceptin analogs.

Functional characterization of opioid receptor ligands by aequorin luminescence-based calcium assay.

[D-1-Nal4]endomorphin-2 is a potent micro-opioid receptor antagonist in the aequorin luminescence-based calcium assay.

Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice.

In vitro characterization of novel peptide inhibitors of endomorphin-degrading enzymes in the rat brain.

Characterization of tachykinin-related peptides from different insect species on Drosophila tachykinin receptor-expressing cell line.

[Opioid receptors and their selective ligands].

Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure.

[Dmt1, d-1-Nal3]morphiceptin, a novel opioid peptide analog with high analgesic activity.

Opioid-induced regulation of mu-opioid receptor gene expression in the MCF-7 breast cancer cell line.

Enzymatic degradation of endomorphins.

Opioid antagonist-induced regulation of the mu-opioid receptor expression in MCF-7 breast cancer cell line.

Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2.

The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line.

Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction.

Synthesis and biological evaluation of novel peripherally active morphiceptin analogs.

Synthesis and biological evaluation of new salvinorin A analogues incorporating natural amino acids.

The role of morphine in regulation of cancer cell growth.

Effect of 2',6'-dimethyl-L-tyrosine (Dmt) on pharmacological activity of cyclic endomorphin-2 and morphiceptin analogs.

Natural and synthetic α-methylenelactones and α-methylenelactams with anticancer potential.

Kinetic studies of novel inhibitors of endomorphin degrading enzymes.

Brain-Gut Interactions in IBS.

The mu-opioid receptor-selective peptide antagonists, antanal-1 and antanal-2, produce anticonvulsant effects in mice.

Non-specific abdominal pain and air pollution: a novel association.

Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives.

Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract.

A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice.

Pharmacological properties of novel cyclic pentapeptides with µ-opioid receptor agonist activity.

Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases.

Novel glycosylated endomorphin-2 analog produces potent centrally-mediated antinociception in mice after peripheral administration.

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases.

Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.

Antinociceptive effects of novel melatonin receptor agonists in mouse models of abdominal pain.

Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review.

Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.

Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.

Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2.

Cross-talk between serotonin and cannabinoid signaling in the gut, new insights and future perspectives.

Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases.

Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases.

Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: new potential treatment of abdominal pain associated with inflammatory bowel diseases.

Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors.

Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors.

Prevention and therapeutic strategies of thromboembolic events in patients with inflammatory bowel diseases: a report of three cases.

Role of transient receptor potential channels in intestinal inflammation and visceral pain: novel targets in inflammatory bowel diseases.

Role of G protein-coupled orphan receptors in intestinal inflammation: novel targets in inflammatory bowel diseases.

Comment on "Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota".

Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome.

Ischemic colitis: current diagnosis and treatment.

What is the Future of the Gut Microbiota-Related Treatment? Toward Modulation of Microbiota in Preventive and Therapeutic Medicine.

Experimental colitis in mice is attenuated by topical administration of chlorogenic acid.

The link between cardiovascular and circulatory events in inflammatory gastrointestinal disorders.

Beneficial Effects of Probiotics, Prebiotics, Synbiotics, and Psychobiotics in Inflammatory Bowel Disease.

Neutrophil-lymphocyte ratio in Crohn's disease patients predicts sustained response to infliximab 52-week therapy.

Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome.

Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.

Polyphenols as mitochondria-targeted anticancer drugs.

Cannabinoids regulate intestinal motor function and electrophysiological activity of myocytes in rodents.

Nociceptin effect on intestinal motility depends on opioid-receptor like-1 receptors and nitric oxide synthase co-localization.

Comment on Choi et al.: High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes.

The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective.

A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.

Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.

Silver and other metals in the treatment of gastrointestinal diseases.

Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.

Encenicline, an α7 Nicotinic Acetylcholine Receptor Partial Agonist, Reduces Immune Cell Infiltration in the Colon and Improves Experimental Colitis in Mice.

Role of environmental pollution in irritable bowel syndrome.

Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner.

Expression and physiology of opioid receptors in the gastrointestinal tract.

Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.

Enhancement of anticancer potential of polyphenols by covalent modifications.

RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives.

Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment.

Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice.

Rhenium-coated glass beads for intracolonic administration attenuate TNBS-induced colitis in mice: Proof-of-Concept Study.

Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice.

Anticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice.

LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity.

Inflammatory bowel diseases and reproductive health.

Is insulin-like growth factor 1 (IGF-1) system an attractive target inflammatory bowel diseases? Benefits and limitation of potential therapy.

Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.

Circadian rhythm abnormalities - Association with the course of inflammatory bowel disease.

The influence of family pattern abnormalities in the early stages of life on the course of inflammatory bowel diseases.

Common links between metabolic syndrome and inflammatory bowel disease: Current overview and future perspectives.

Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.

Inflammatory bowel disease treatment.

Elevated risk of venous thromboembolic events in patients with inflammatory myopathies.

PhDs in academic gastroenterology: key to a successful career.

Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome.

Alopecia areata in patients with inflammatory bowel disease: an overview.

The influence of lipoic acid on caveolin-1-regulated antioxidative enzymes in the mouse model of acute ulcerative colitis.

Synthesis and evaluation of anti-inflammatory properties of silver nanoparticle suspensions in experimental colitis in mice.

Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.

Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer.

The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis.

Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.

Future Treatment of Constipation-associated Disorders: Role of Relamorelin and Other Ghrelin Receptor Agonists.

Evaluation of anti-inflammatory effect of silver-coated glass beads in mice with experimentally induced colitis as a new type of treatment in inflammatory bowel disease.

G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.

G Protein-Coupled Receptor 30 (GPR30) Expression Pattern in Inflammatory Bowel Disease Patients Suggests its Key Role in the Inflammatory Process. A Preliminary Study.

Cannabinoid Receptor Type 1 and mu-Opioid Receptor Polymorphisms Are Associated With Cyclic Vomiting Syndrome.

Dual Functional Capability of Dendritic Cells - Cytokine-Induced Killer Cells in Improving Side Effects of Colorectal Cancer Therapy.

Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn's Disease.

Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal.

New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration.

Development of the rectal dosage form with silver-coated glass beads for local-action applications in lower sections of the gastrointestinal tract.

Estrogen signaling deregulation related with local immune response modulation in irritable bowel syndrome.

Flavanols from Japanese quince (Chaenomeles japonica) fruit suppress expression of cyclooxygenase-2, metalloproteinase-9, and nuclear factor-kappaB in human colon cancer cells.

Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study.

Fat-soluble Vitamin Deficiencies and Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.

Young GI angle: The role of bibliometrics in scientist's career development.

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.

Evaluation of Melatonin Secretion and Metabolism Exponents in Patients with Ulcerative and Lymphocytic Colitis.

Novel derivatives of 1,2,3-triazole, cannabinoid-1 receptor ligands modulate gastrointestinal motility in mice.

The mechanisms linking obesity to colon cancer: An overview.

Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension-proof-of-concept.

Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe-p-CF-Phe-Asp]NH.

Alanine scan of sialorphin and its hybrids with opiorphin: synthesis, molecular modelling and effect on enkephalins degradation.

Bile acids and FXR in functional gastrointestinal disorders.

Inflammation-associated changes in DOR expression and function in the mouse colon.

Chronic abdominal pain in irritable bowel syndrome - current and future therapies.

Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disorders.

Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Diagnostic value of chemerin in lower gastrointestinal diseases-a review.

New Trends in Liposome-based Drug Delivery in Colorectal Cancer.

Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH) with anti-inflammatory activity in the mouse models of colitis.

Young GI angle: My biggest (career) mistake.

Enkephalin degradation in serum of patients with inflammatory bowel diseases.

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron.

One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool?

The role of adipose tissue in the pathogenesis of Crohn's disease.

Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders.

Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain.

Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system.

High activity of the endogenous opioid system and acute but not chronic stress influence experimental colitis development in mice.

High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury.

Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus.

G protein-coupled estrogen receptor mediates anti-inflammatory action in Crohn's disease.

Effectiveness and therapeutic value of phytochemicals in acute pancreatitis: A review.

Changes in the diet composition of fatty acids and fiber affect the lower gastrointestinal motility but have no impact on cardiovascular parameters: In vivo and in vitro studies.

Comparison of the efficacy of available statistical methods for prediction of the hospitalizations number: proof of concept and validation based on the analysis of Polish National Health Fund data in the years 2009-2017.

Sex- and Age-Related Estrogen Signaling Alteration in Inflammatory Bowel Diseases: Modulatory Role of Estrogen Receptors.

1-Substituted sialorphin analogues-synthesis, molecular modelling and in vitro effect on enkephalins degradation by NEP.

Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen.

Evaluation of the effect of liposomes loaded with chlorogenic acid in treatment of 2,4,6-trinitrobenzenesulfonic acid-induced murine colitis.

Organometallic Compounds and Metal Complexes in Current and Future Treatments of Inflammatory Bowel Disease and Colorectal Cancer-a Critical Review.

Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial.

Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43].

Corrigendum to "Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system" [Biochem. Pharmacol. 161 (2019) 37-51].

Gut microbiota: what is its place in pharmacology?

Chain length of dietary fatty acids determines gastrointestinal motility and visceromotor function in mice in a fatty acid binding protein 4-dependent manner.

Free Fatty Acid Receptors as new potential target in Colorectal Cancer.

Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome.

Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists suggest their Potential Use in Irritable Bowel Syndrome with Constipation: A Systematic Review and Meta-Analysis.

Free Fatty Acid Receptors as new potential therapeutic target in inflammatory bowel diseases.

Biologic Therapy in Crohn's Disease - What We Learnt so far.

[Strategies in Crohn's disease treatment - "step-up" vs. "top-down"].

Opioids in Cancer Development, Progression and Metastasis: Focus on Colorectal Cancer.

Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen.

Evaluation of anti-inflammatory effect of silver-coated glass beads in mice with experimentally induced colitis as a new type of treatment in inflammatory bowel disease.

Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract.

Chemerin in immune response and gastrointestinal pathophysiology.

Biomarkers for early detection of colitis-associated colorectal cancer - current concepts, future trends.

Cyclic derivatives of morphiceptin possess anti-transit effect in the gastrointestinal tract and alleviate abdominal pain in mice.